Cervical Preparation in Hysteroscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-23

Study Completion Date

2019-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hysteroscopy was performed in the proliferativephase of the menstrual cycle.

The patients were given generalintravenous anesthesia (propofol/fentanyl) after the vulvar and the vaginal area had been disinfected with a 7.5% Betadinesolution by the surgical nurse All operations were performed by the same surgeon to avoid possible discrepancies between different surgeons.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

NCT04044079

Office Hysteroscopy

COMPLETED PHASE4

Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

NCT03683914

Office Hysteroscopy

COMPLETED PHASE4

Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients

NCT04042974

Hysteroscopy

UNKNOWN PHASE4

Optimal Timing of Dinoprostone Administration Prior to Office Hysteroscopy

NCT04085757

Dinoprostone Timing

COMPLETED PHASE3

Intravaginal Misoprostol Versus Dinoprostone Before Diagnostik Hysteroscopy

NCT01620814

Cervical Ripening

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Astandard rigid30 hysteroscope (Karl Storz bettocchi hysteroscope) with a 30° viewing angleand an outer sheath diameter 5.5 mm, inner sheath diameter 4.3 mm and scope diameter 2.9 mmwas used in all procedures.

A speculum was introduced into the vagina, and the uterine cervixwas visualized. Initially, the surgeon attempted to passthrough the cervical canal with the tool directly. When thatwas not possible or when the cervical canal was too rigid ortoo tight, the cervix was grasped with a tenaculum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GYN Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm number one ,misoprostol

Group Type ACTIVE_COMPARATOR

misoprostol

Intervention Type DRUG

giving misoprostol to this group

Arm number 2 dinoprostone

Group Type ACTIVE_COMPARATOR

dinoprostone

Intervention Type DRUG

giving dinoprostine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

misoprostol

giving misoprostol to this group

Intervention Type DRUG

dinoprostone

giving dinoprostine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients of reproductive age
2. have undergone a cesarean section at least once
3. an indication for diagnostic hysteroscopy for menstrualproblems or suspected intrauterine lesions (suchas uterine polyps and ﬁlling defects in the uterine cavity) by abnormal ﬁndings from hysterosalpingography,ultrasonography, or saline infusion sonography.

Exclusion Criteria

1. Patients who delivered vaginally
2. Had undergone any other transcervical or transabdominal uterine and cervical intervention other than cesareansection, such as loop electrosurgical procedures, cervical cryotherapy, cervical biopsies, and spontaneousabortions, previous dilation, and previous electiveabortions.
3. Patients with cervical pathology,e.g. tears or polyps.
4. The patients with a contraindicationto prostaglandins such as hypersensitivity, bronchial asthma, glaucoma, severeasthma, cardiac, liver or kidney diseases.

\-

Minimum Eligible Age

20 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes